Evaluation of bleeding risk in patients who received pirtobrutinib in the presence or absence of antithrombotic therapy

Documenti analoghi

• Successful treatment of acyclovir‐resistant herpes simplex virus infection with amenamevir in a patient who received umbilical cord blood transplantation for T‐cell prolymphocytic leukemia
  di: Yuma Kawamura, et al.
  Pubblicazione: (2024)
• Effectiveness of emicizumab in preventing bleeding events in severe and moderate hemophilia A: A single‐center experience in Bangladesh
  di: Sanzina Sadia Tory, et al.
  Pubblicazione: (2024)
• Real‐world characteristics and outcomes of patients with multiple myeloma receiving second‐line treatment in England
  di: Sally Moore, et al.
  Pubblicazione: (2024)
• Real‐world outcomes of patients with relapsed/refractory large B‐cell lymphoma receiving second‐line therapy in England
  di: Christopher P. Fox, et al.
  Pubblicazione: (2024)
• The association of donor and recipient sex on sepsis rates and hemoglobin increment among critically ill patients receiving red cell transfusions in a retrospective study
  di: Wenhui Li, et al.
  Pubblicazione: (2025)